110 related articles for article (PubMed ID: 37862791)
1. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Ledermann JA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Kobie J; Nebozhyn M; Edmondson M; Sun Y; Cristescu R; Jelinic P; Keefe SM; Matulonis UA
Gynecol Oncol; 2023 Nov; 178():119-129. PubMed ID: 37862791
[TBL] [Abstract][Full Text] [Related]
2. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
Shitara K; Di Bartolomeo M; Mandala M; Ryu MH; Caglevic C; Olesinski T; Chung HC; Muro K; Goekkurt E; McDermott RS; Mansoor W; Wainberg ZA; Shih CS; Kobie J; Nebozhyn M; Cristescu R; Cao ZA; Loboda A; Özgüroğlu M
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399357
[TBL] [Abstract][Full Text] [Related]
3. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
Loi S; Salgado R; Schmid P; Cortes J; Cescon DW; Winer EP; Toppmeyer DL; Rugo HS; De Laurentiis M; Nanda R; Iwata H; Awada A; Tan AR; Sun Y; Karantza V; Wang A; Huang L; Saadatpour A; Cristescu R; Yearley J; Lunceford J; Jelinic P; Adams S
JCO Precis Oncol; 2023 Apr; 7():e2200317. PubMed ID: 37099733
[TBL] [Abstract][Full Text] [Related]
4. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Bellmunt J; de Wit R; Fradet Y; Climent MA; Petrylak DP; Lee JL; Fong L; Necchi A; Sternberg CN; O'Donnell PH; Powles T; Plimack ER; Bajorin DF; Balar AV; Castellano D; Choueiri TK; Culine S; Gerritsen W; Gurney H; Quinn DI; Vuky J; Vogelzang NJ; Cristescu R; Lunceford J; Saadatpour A; Loboda A; Ma J; Rajasagi M; Godwin JL; Homet Moreno B; Grivas P
Clin Cancer Res; 2022 May; 28(10):2050-2060. PubMed ID: 35247908
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Gutierrez M; Lam WS; Hellmann MD; Gubens MA; Aggarwal C; Tan DSW; Felip E; Chiu JWY; Lee JS; Yang JC; Garon EB; Finocchiaro G; Ahn MJ; Luft A; Landers GA; Basso A; Ma H; Kobie J; Palcza J; Cristescu R; Fong L; Snyder A; Yuan J; Herbst RS
Nat Med; 2023 Jul; 29(7):1718-1727. PubMed ID: 37429923
[TBL] [Abstract][Full Text] [Related]
6. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
7. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Cristescu R; Nebozhyn M; Zhang C; Albright A; Kobie J; Huang L; Zhao Q; Wang A; Ma H; Alexander Cao Z; Morrissey M; Ribas A; Grivas P; Cescon DW; McClanahan TK; Snyder A; Ayers M; Lunceford J; Loboda A
Clin Cancer Res; 2022 Apr; 28(8):1680-1689. PubMed ID: 34965943
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker V; Taylor MH; Aghajanian C; Cohn AL; Brose MS; Simone CD; Cao ZA; Suttner L; Loboda A; Cristescu R; Jelinic P; Orlowski R; Dutta L; Matsui J; Dutcus CE; Minoshima Y; Messing MJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242717
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis UA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Katchar K; Wu H; Keefe S; Ruman J; Ledermann JA
Ann Oncol; 2019 Jul; 30(7):1080-1087. PubMed ID: 31046082
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Caglevic C; Chung HC; Muro K; Van Cutsem E; Kobie J; Cristescu R; Aurora-Garg D; Lu J; Shih CS; Adelberg D; Cao ZA; Fuchs CS
Ann Oncol; 2021 Sep; 32(9):1127-1136. PubMed ID: 34082019
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Pfister DG; Haddad RI; Worden FP; Weiss J; Mehra R; Chow LQM; Liu SV; Kang H; Saba NF; Wirth LJ; Sukari A; Massarelli E; Ayers M; Albright A; Webber AL; Mogg R; Lunceford J; Huang L; Cristescu R; Cheng J; Seiwert TY; Bauml JM
Cancer Med; 2023 Mar; 12(6):6603-6614. PubMed ID: 36479637
[TBL] [Abstract][Full Text] [Related]
15. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.
Watson GA; Sanz-Garcia E; Zhang WJ; Liu ZA; Yang SC; Wang B; Liu S; Kubli S; Berman H; Pfister T; Genta S; Spreafico A; Hansen AR; Bedard PL; Lheureux S; Abdul Razak A; Cescon D; Butler MO; Xu W; Mak TW; Siu LL; Chen E
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705312
[TBL] [Abstract][Full Text] [Related]
18. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Hu-Lieskovan S; Lisberg A; Zaretsky JM; Grogan TR; Rizvi H; Wells DK; Carroll J; Cummings A; Madrigal J; Jones B; Gukasyan J; Shintaku IP; Slamon D; Dubinett S; Goldman JW; Elashoff D; Hellmann MD; Ribas A; Garon EB
Clin Cancer Res; 2019 Aug; 25(16):5061-5068. PubMed ID: 31113840
[TBL] [Abstract][Full Text] [Related]
19. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
20. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
